美国 · SEC FORM 4
RAPT Therapeutics, Inc.
RAPT · — · CIK 0001673772 · Healthcare
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
0 同一窗口内观察到的 Form 4 交易行
0 sales · 0 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
内部人活动时间轴
当前 180 天窗口内没有 Form 4 交易事件。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2023-03-14 · Robbins Wendye.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
FINRA 报告中没有该股票代码的空头余额。
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2023-03-14 | Robbins Wendye | 买入 (P) | Common Stock | 5,000 | USD 19.52 | USD 97,612 | SEC 申报 ↗ |
| 2022-05-25 | COLUMN GROUP II, LP; Column Group IV GP, LP; Column Group IV, LP; Column Group IV-A, LP; TCG IV GP, LLC | 买入 (P) | Common Stock | 1,900 | USD 12.45 | USD 23,655 | SEC 申报 ↗ |
| 2022-05-25 | COLUMN GROUP II, LP; Column Group II GP, LP; Column Group LLC; GOEDDEL DAVID V; Kutzkey Tim; PONOI CAPITAL, LP; Ponoi Capital II, LP; Ponoi II Management, LLC; Ponoi Management, LLC; Svennilson Peter | 买入 (P) | Common Stock | 1,900 | USD 12.45 | USD 23,655 | SEC 申报 ↗ |
| 2022-05-24 | COLUMN GROUP II, LP; Column Group IV GP, LP; Column Group IV, LP; Column Group IV-A, LP; TCG IV GP, LLC | 买入 (P) | Common Stock | 16,314 | USD 12.00 | USD 195,768 | SEC 申报 ↗ |
| 2022-05-24 | COLUMN GROUP II, LP; Column Group II GP, LP; Column Group LLC; GOEDDEL DAVID V; Kutzkey Tim; PONOI CAPITAL, LP; Ponoi Capital II, LP; Ponoi II Management, LLC; Ponoi Management, LLC; Svennilson Peter | 买入 (P) | Common Stock | 16,314 | USD 12.00 | USD 195,768 | SEC 申报 ↗ |
| 2022-05-23 | COLUMN GROUP II, LP; Column Group IV GP, LP; Column Group IV, LP; Column Group IV-A, LP; TCG IV GP, LLC | 买入 (P) | Common Stock | 10,236 | USD 12.50 | USD 127,950 | SEC 申报 ↗ |
| 2022-05-23 | COLUMN GROUP II, LP; Column Group II GP, LP; Column Group LLC; GOEDDEL DAVID V; Kutzkey Tim; PONOI CAPITAL, LP; Ponoi Capital II, LP; Ponoi II Management, LLC; Ponoi Management, LLC; Svennilson Peter | 买入 (P) | Common Stock | 10,236 | USD 12.50 | USD 127,950 | SEC 申报 ↗ |
| 2022-05-10 | Young Rodney KB | 买入 (P) | Common Stock | 5,000 | USD 10.53 | USD 52,650 | SEC 申报 ↗ |
| 2022-05-10 | Robbins Wendye | 买入 (P) | Common Stock | 7,000 | USD 11.04 | USD 77,282 | SEC 申报 ↗ |
| 2022-05-10 | COLUMN GROUP II, LP; Column Group IV GP, LP; Column Group IV, LP; Column Group IV-A, LP; TCG IV GP, LLC | 买入 (P) | Common Stock | 1,250,000 | USD 10.67 | USD 13,337,500 | SEC 申报 ↗ |
| 2022-05-10 | COLUMN GROUP II, LP; Column Group II GP, LP; Column Group LLC; GOEDDEL DAVID V; Kutzkey Tim; PONOI CAPITAL, LP; Ponoi Capital II, LP; Ponoi II Management, LLC; Ponoi Management, LLC; Svennilson Peter | 买入 (P) | Common Stock | 1,250,000 | USD 10.67 | USD 13,337,500 | SEC 申报 ↗ |
| 2021-10-18 | Robbins Wendye | 买入 (P) | Common Stock | 500 | USD 30.70 | USD 15,350 | SEC 申报 ↗ |
| 2021-10-13 | Robbins Wendye | 买入 (P) | Common Stock | 400 | USD 29.69 | USD 11,876 | SEC 申报 ↗ |
| 2021-08-24 | Robbins Wendye | 买入 (P) | Common Stock | 525 | USD 30.99 | USD 16,270 | SEC 申报 ↗ |
| 2021-08-23 | Robbins Wendye | 买入 (P) | Common Stock | 1,475 | USD 31.38 | USD 46,292 | SEC 申报 ↗ |
Form 4 申报证据
15 transaction lines in the latest 365-day window; 307 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-03-03 | Young Rodney KB | U (U) | Common Stock | 3,304 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-03 | Wong Brian Russell | U (U) | Common Stock | 64,102 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-03 | Lyons-Williams Lori | U (U) | Common Stock | 4,956 | USD — | USD — | SEC 申报 ↗ |
展开近期 Form 4 证据 (15 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-03-03 | Young Rodney KB | U (U) | Common Stock | 3,304 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-03 | Wong Brian Russell | U (U) | Common Stock | 64,102 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-03 | Lyons-Williams Lori | U (U) | Common Stock | 4,956 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-03 | Kozick Linda | U (U) | Common Stock | 4,956 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-03 | Giordano Michael F | U (U) | Common Stock | 4,956 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-03 | GRAY MARY ANN | U (U) | Common Stock | 4,956 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-03 | Dombkowski Ashley L. | U (U) | Common Stock | 4,956 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-03 | Brockstedt Dirk G. | U (U) | Common Stock | 4,648 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-03 | Braunstein Scott | U (U) | Common Stock | 4,956 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-30 | Lyons-Williams Lori | 奖励/授予 (A) | Common Stock | 4,956 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-30 | Kozick Linda | 奖励/授予 (A) | Common Stock | 4,956 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-30 | Giordano Michael F | 奖励/授予 (A) | Common Stock | 4,956 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-30 | GRAY MARY ANN | 奖励/授予 (A) | Common Stock | 4,956 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-30 | Dombkowski Ashley L. | 奖励/授予 (A) | Common Stock | 4,956 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-30 | Braunstein Scott | 奖励/授予 (A) | Common Stock | 4,956 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | RAPT |
| CIK | 0001673772 |
| 行业 | Healthcare |
| 细分行业 | — Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | — |
数据覆盖
| 本地 Form 4 历史 | 307 transaction lines from 2020-01-30 to 2026-03-03 70 P purchase lines · 144 S sale lines · 93 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.